Handok-Genexine co-develop growth hormone, selected as orphan drug from FDA
‘GX-H9,’ a long-acting growth hormone that is being co-developed by Handok(Chairman Young-Jin Kim) and Genexine(CEO Han-Soo Kyung), was selected as an orphan drug to treat growth hormone deficiency from the U.S. Food and Drug Administration(FDA) on the 9th of November.
Growth hormone is a prot...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
